| 2025-11-12 |
详情>>
股本变动：
变动后总股本18468.96万股
|
| 2025-11-12 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-0.72美元,归母净利润-2.66亿美元,同比去年增长-30.83%
|
| 2025-11-12 |
财报披露：
美东时间 2025-11-12 盘前发布财报
|
| 2025-08-11 |
详情>>
业绩披露：
2025年中报每股收益-0.62美元,归母净利润-2.26亿美元,同比去年增长-190.16%
|
| 2025-05-13 |
详情>>
业绩披露：
2025年一季报每股收益-0.27美元,归母净利润-1.01亿美元,同比去年增长-68.78%
|
| 2025-05-12 |
股东大会：
将于2025-06-12召开股东大会
会议内容 ▼▲
- 1.To receive the audited consolidated financial statements of the Company for the fiscal year ended December 31, 2024.
2.To ratify the appointment of Ernst & Young LLP as independent auditor of the Company (the “Independent Auditor”) for the fiscal year ending December 31, 2025.
3.To re-elect Dr. Patrick Casey, whose term of office will expire pursuant to article 88(b) of the Company’s memorandum of association, to serve as a Class II director of the Company for a full term of three (3) years.
4.To re-elect Yau Wai Man Philip, whose term of office will expire pursuant to article 88(b) of the Company’s memorandum of association, to serve as a Class II director of the Company for a full term of three (3) years.
5.To re-elect Dr. Fangliang Zhang, whose term of office will expire pursuant to article 88(b) of the Company’s memorandum of association, to serve as a Class II director of the Company for a full term of three (3) years.
6.To authorize each of the directors and officers of the Company to take any and every action that might be necessary to effect the foregoing resolutions as such director or officer, in his or her absolute discretion, thinks fit.
|
| 2025-03-11 |
详情>>
业绩披露：
2024年年报每股收益-0.48美元,归母净利润-1.77亿美元,同比去年增长65.84%
|
| 2025-03-11 |
详情>>
业绩披露：
2022年年报每股收益-1.4美元,归母净利润-4.46亿美元,同比去年增长-10.6%
|
| 2024-11-12 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-0.56美元,归母净利润-2.03亿美元,同比去年增长45.56%
|
| 2024-08-09 |
详情>>
业绩披露：
2024年中报每股收益-0.21美元,归母净利润-7798.9万美元,同比去年增长74.94%
|
| 2024-05-13 |
详情>>
业绩披露：
2024年一季报每股收益-0.16美元,归母净利润-5979.3万美元,同比去年增长46.66%
|
| 2024-03-19 |
详情>>
业绩披露：
2023年年报每股收益-1.47美元,归母净利润-5.18亿美元,同比去年增长-16.11%
|
| 2023-11-20 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-1.07美元,归母净利润-3.73亿美元,同比去年增长-20.28%
|
| 2023-08-21 |
股东大会：
将于2023-09-21召开股东大会
会议内容 ▼▲
- 1.To receive the audited consolidated financial statements of the Company for the fiscal year ended December 31, 2022.
2.To ratify the appointment of Ernst & Young LLP as independent auditor of the Company (the “Independent Auditor”) for the fiscal year ending December 31, 2023.
3.To re-elect Dr. Li Zhu, whose term of office will expire pursuant to article 88(b) of the Company’s memorandum of association, to serve as a Class III director of the Company for a full term of three (3) years.
4.To re-elect Dr. Corazon D. Sanders, whose term of office will expire pursuant to article 88(b) of the Company’s memorandum of association, to serve as a Class III director of the Company for a full term of three (3) years.
5.To re-elect Dr. Li Mao, whose term of office will expire pursuant to article 88(b) of the Company’s memorandum of association, to serve as a Class III director of the Company for a full term of three (3) years.
6.To authorize each of the directors and officers of the Company to take any and every action that might be necessary to effect the foregoing resolutions as such director or officer, in his or her absolute discretion, thinks fit.
|
| 2022-09-16 |
股东大会：
将于2022-10-14召开股东大会
会议内容 ▼▲
- 1.Reception of the audited consolidated financial statements of the company for the fiscal year ended december 31, 2021.
2.Ratification of the appointment of ernst & young llp as independent auditor of the company.
3.Re-election of Dr. Patrick casey as a director of the company.
4.Re-election of Mr. Philip yau as a director of the company.
5.Re-election of dr. Fangliang zhang as a director of the company.
6.Authorization of each of the directors and officers of the company.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-05-05 |
股东大会：
将于2021-06-09召开股东大会
会议内容 ▼▲
- 1.To receive the audited consolidated financial statements of the Company for the fiscal year ended December 31, 2020.
2.To ratify the re-appointment of Ernst & Young Hua Ming LLP as independent auditor of the Company (the “Independent Auditor”) for the fiscal year ending December 31, 2021.
3.To re-elect Ms. Ye Wang, whose term of office will expire pursuant to article 88(b) of the Company’s memorandum of association, to serve as a Class I director of the Company for a full term of three (3) years.
4.To re-elect Dr. Darren Xiaohui Ji, whose term of office will expire pursuant to article 88(b) of the Company’s memorandum of association, to serve as a Class I director of the Company for a full term of three (3) years.
5.To authorize each of the directors and officers of the Company to take any and every action that might be necessary to effect the foregoing resolutions as such director or officer, in his or her absolute discretion, thinks fit.
|